Engineered brain cells offer new hope for treating Alzheimer's

Engineering viral vectors for acoustically targeted gene delivery

Targeted gene delivery to the brain is a critical tool for neuroscience research and has significant potential to treat human disease. However, the site-specific delivery of common gene vectors such as adeno-associated viruses (AAVs) is typically performed via invasive injections, which limit its applicable scope of research and clinical applications. Alternatively, focused ultrasound blood-brain-barrier opening (FUS-BBBO), performed noninvasive…

Shifting paradigms of clinical trial design accelerate CNS R&D

Alzheimer’s drug developers are now at the forefront of adopting more nuanced, cost-effective, and patient-centric clinical trial designs.

The European Commission has approved a drug for the mild form of Alzheimer's disease. The first treatments are expected to begin in Slovenia by the end of the year.

Engineered microglia show promise for treating Alzheimer's and other brain diseases

A new way to deliver disease-fighting proteins throughout the brain may improve the treatment of Alzheimer's disease and other neurological disorders, according to scientists. By engineering human immune cells called microglia, the researchers have created living cellular 'couriers' capable of responding to brain pathology and releasing therapeutic agents exactly where needed.

Engineered brain cells offer new hope for treating Alzheimer's

A new way to deliver disease-fighting proteins throughout the brain may improve the treatment of Alzheimer's disease and other neurological disorders, according to University of California, Irvine scientists.

UT Health San Antonio researchers may be able to turn IV drugs into oral treatment for Alzheimer's

They said they found a new strategy that allows the body to use its own protein receptors to help the drugs enter cells more efficiently.